Predicting Severity and Prognosis in Myocarditis from Immune Checkpoint Inhibitors
Author Information
Author(s): Li Zhenli, Yao Tiezhu, Liu Guang, Guan Zhengkun, Liu Jing, Guo Ling, Ma Jingtao
Primary Institution: The Fourth Hospital of Hebei Medical University
Hypothesis
The study aimed to establish nomograms based on ratio biomarkers to predict the severity and prognosis of immune checkpoint inhibitors-related myocarditis (ICI-M).
Conclusion
Ratio indexes at onset and their change rates from baseline showed good diagnostic value for the severity of ICI-M and prognostic value for subsequent major adverse cardiovascular events (MACEs).
Supporting Evidence
- Seventy-seven patients were involved, including 31 severe cases (40.3%).
- Lactate dehydrogenase-to-albumin ratio (LAR) combined with the change rate from baseline to onset of LAR performed best to diagnose severe ICI-M.
- The bootstrap-corrected concordance index was 0.752 with a 95% confidence interval of 0.635-0.866.
- A ≥101% increase in LAR significantly separated patients in MACE-free survival.
Takeaway
Doctors can use certain blood test ratios to tell how serious heart problems are in patients getting cancer treatment with immune checkpoint inhibitors.
Methodology
The study retrospectively examined patients with advanced cancers diagnosed with ICI-M, dividing them into mild and severe groups, and established nomogram-based models for prediction.
Potential Biases
Potential bias due to the retrospective design and reliance on electronic medical records.
Limitations
The low prevalence of ICI-M and the retrospective nature of the study may limit the generalizability of the models.
Participant Demographics
The study included 77 patients, with 54 males (70.13%) and 23 females (29.87%), median age of 67 years.
Statistical Information
P-Value
p=0.036
Confidence Interval
95% CI: 0.635-0.866
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website